论文部分内容阅读
T2DM患者普遍存在肠促胰素效应受损。胰升血糖素样肽-1(GLP-1)是最重要的一种肠促胰素,可葡萄糖依赖性刺激胰岛β细胞分泌胰岛素、抑制a细胞不适当分泌胰升血糖素,从而改善患者的血糖控制,并且不增加低血糖风险。因此,基于肠促胰素药物是治疗T2DM的新策略,其中包括GLP-1受体激动剂和二肽基肽酶-4(DPP-4)抑制剂两大类。本文对各种基于肠促胰素药物的优缺点进行评述。
Patients with T2DM are generally impaired by the effects of the incretin hormone. Glucagon-like peptide-1 (GLP-1) is the most important type of incretin which can glucose-dependently stimulate islet β-cells to secrete insulin and inhibit a cell from inappropriate secretion of glucagon, thereby improving the patient’s Blood glucose control, and does not increase the risk of hypoglycemia. Therefore, incretin-based drugs are new strategies for the treatment of T2DM, including two broad categories of GLP-1 receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. This article reviews the advantages and disadvantages of various incretin-based drugs.